These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 23032499)

  • 1. [Should we treat thalassemia-induced osteoporosis: two case reports].
    Lucini M; Stoll D; Aubry-Rozier B; Lamy O
    Praxis (Bern 1994); 2012 Oct; 101(20):1325-9. PubMed ID: 23032499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. To treat osteoporosis, Denosumab appears more effective than Zoledronate. Denosumab has the advantage in building bone density, and has fewer side effects.
    Duke Med Health News; 2014 Mar; 20(3):1-2. PubMed ID: 24683617
    [No Abstract]   [Full Text] [Related]  

  • 3. [Advances in the field of osteoporosis].
    Vignot E; Delmas PD
    Rev Prat; 2007 Oct; 57(15):1629-31. PubMed ID: 18080418
    [No Abstract]   [Full Text] [Related]  

  • 4. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
    Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
    Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Inhibition of RANK ligand to treat bone metastases].
    Body JJ
    Bull Cancer; 2013 Nov; 100(11):1207-13. PubMed ID: 24158618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoporosis medications and your dental health.
    J Am Dent Assoc; 2011 Nov; 142(11):1320. PubMed ID: 22041419
    [No Abstract]   [Full Text] [Related]  

  • 7. Denosumab and bone metastases. No better than a bisphosphonate.
    Prescrire Int; 2012 Sep; 21(130):204-6. PubMed ID: 23016249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone recovery after zoledronate therapy in thalassemia-induced osteoporosis: a meta-analysis and systematic review.
    Mamtani M; Kulkarni H
    Osteoporos Int; 2010 Jan; 21(1):183-7. PubMed ID: 19242634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New bone density conservation agents for osteoporosis under research and development: Zoledronate].
    Wada S; Fukawa T; Kamiya S
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():421-5. PubMed ID: 18161143
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia.
    Perifanis V; Vyzantiadis T; Tziomalos K; Vakalopoulou S; Garipidou V; Athanassiou-Metaxa M; Harsoulis F
    Ann Hematol; 2007 Jan; 86(1):23-30. PubMed ID: 17013645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
    Skordis N; Ioannou YS; Kyriakou A; Savva SC; Efstathiou E; Savvides I; Christou S
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():144-8. PubMed ID: 19337169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin D status and parathyroid hormone concentrations influence the skeletal response to zoledronate and denosumab.
    Mosali P; Bernard L; Wajed J; Mohamed Z; Ewang M; Moore A; Fogelman I; Hampson G
    Calcif Tissue Int; 2014 May; 94(5):553-9. PubMed ID: 24509506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increasing options for the treatment of osteoporosis.
    Khosla S
    N Engl J Med; 2009 Aug; 361(8):818-20. PubMed ID: 19671654
    [No Abstract]   [Full Text] [Related]  

  • 14. Skeletal-related events in metastatic prostate cancer and the number needed to treat: a critical consideration.
    Schmitz-Dräger BJ; Weiss C; Ebert T; Dörsam J; Bismarck E
    Urol Int; 2013; 90(3):329-33. PubMed ID: 23407093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [[Antiresorptive agents in the treatment of osteoporosis].
    Novak S
    Reumatizam; 2014; 61(2):89-94. PubMed ID: 25427401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Taurine deficiency in thalassemia major-induced osteoporosis treated with neridronate.
    D'Eufemia P; Finocchiaro R; Celli M; Raccio I; Zambrano A; Tetti M; Smacchia P; Iacobini M
    Biomed Pharmacother; 2010 Apr; 64(4):271-4. PubMed ID: 20359847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denosumab an option for patients with bone metastasis from breast cancer.
    Barton MK
    CA Cancer J Clin; 2011; 61(3):135-6. PubMed ID: 21532096
    [No Abstract]   [Full Text] [Related]  

  • 18. [When should bisphosphonate treatment be discontinued?].
    Eriksen EF; Halse J
    Tidsskr Nor Laegeforen; 2012 Aug; 132(14):1630-2. PubMed ID: 22875131
    [No Abstract]   [Full Text] [Related]  

  • 19. Summaries for patients. Zolendronic acid prevents bone loss after liver transplantation.
    Ann Intern Med; 2006 Feb; 144(4):I37. PubMed ID: 16490906
    [No Abstract]   [Full Text] [Related]  

  • 20. New and emerging treatments for osteoporosis.
    Maricic M
    Curr Opin Rheumatol; 2007 Jul; 19(4):364-9. PubMed ID: 17551368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.